We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Genzyme Receives Refuse-to-File Letter on MS Indication for Lemtrada
Genzyme Receives Refuse-to-File Letter on MS Indication for Lemtrada
August 31, 2012
The FDA has issued Genzyme a refuse-to-file letter on its sBLA for Lemtrada as a treatment for relapsing multiple sclerosis (MS).